ABOUT ANTENGENE MANAGEMENT TEAM SCIENTIFIC ADVISORY BOARD BOARD OF DIRECTORS INVESTORS

BOARD OF DIRECTORS

Thank you for your interest. The detailed list of board of directors will be announced later.

Jay Mei, M.D., Ph.D.

Dr. Jay Mei is the founder, chairman and CEO of Antengene. Prior to founding the company, Dr. Mei has more than twenty years of cancer research and drug development experience, and worked at the US National Cancer Institute (NCI) as well as several multi-national pharmaceutical companies, including Johnson & Johnson Pharmaceutical R&D (J&JPRD), Novartis Oncology and Celgene Corporation. As an Executive Director of Clinical Development at Celgene Corporation, Dr. Mei successfully led the development of REVLIMID® (Lenalidomide) in China. REVLIMID® received CFDA approval and was launched in China in 2013. Outside the China market, Dr. Mei was responsible for the clinical trials of REVLIMID® in more than 30 countries. He was also the clinical lead at Celgene on IDHIFA® (Enasidenib) which received the FDA approval for relapsed or refractory AML.

Before joining Celgene in 2008, Dr. Mei served in multiple clinical development roles at J&JPRD and Novartis Oncology. Prior to industry, Dr. Mei spent eight years on cancer and clinical research at the NCI. Over more than twenty years of his career in academia and industry, Dr. Mei has been an author on over 70 publications and holds multiple patents.

Dr. Mei graduated from the English Medicine Class, an exchange program sponsored by the Yale China Foundation, at Xiang-Ya Medical College. He subsequently received his Ph.D. in Pharmacology/Toxicology from the University of Maryland in Baltimore. Dr. Mei lectured at the University of Pennsylvania School of Medicine on clinical research and is an adjunct professor at Xiang-Ya Medical College in China.

William Hu, MBA

William Hu is a managing partner of Qiming Venture Partners. William co-leads Qiming’s practice in the healthcare sector and has been closely involved with more than 20 new ventures, some of which have become public or billion dollar market cap companies. On behalf of Qiming, he invested in Tigermed, Tellgen, AmoyDx, Rendu Bio, ET Healthcare, Vinno Medical, APT Medical, Sanyou Orthopedic, Canbridge, Ark Bio, Arrail Dental, JHT Clinics, WeDoctor, Medsci Clinical, and others.

Formerly, William served as a strategy consultant at IBM BCS, and Marketing & Sales management consultant at several pharmaceutical companies.

William holds a Bachelor of Medicine from Shanghai Medical University and MBA from ENPC SH Campus.

Ming Li, Ph.D.

Ming Li is the Vice President of TF Capital. Ming joined TF Capital at its founding and has extensive experience in drug development, pharmaceutical market analysis, consulting and investment. Ming's focus is working with exceptional entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery. Prior to TF Capital, Ming served at the Process Chemistry Department in Novartis, China GlaxoSmithKline R&D Center and IMS Consulting Group.

Ming holds a Doctor of Philosophy from Shanghai Institute of Organic Chemistry and a Postdoctoral from the University of Toulouse III and University of Paris VI.